Quentin M. Anstee

Prof. Quentin M. Anstee

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2017 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
ZYZobair Younossi
Zobair Younossi
QAQuentin M. Anstee
Quentin M. Anstee
MMMilena Marietti
Milena Marietti
THTimothy Hardy
Timothy Hardy
LHLinda Henry
Linda Henry
EBElisabetta Bugianesi
Elisabetta Bugianesi

1 July 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
MEMohammed Eslam
Mohammed Eslam
PNPhilip Noel Newsome
Philip Noel Newsome
SSShiv K. Sarin
Shiv K. Sarin
QAQuentin M. Anstee
Quentin M. Anstee
Giovanni TargherGiovanni Targher
Giovanni Targher
JGJacob George
Jacob George

1 October 2018 in Journal of Hepatology
Verified
Journal Article
Open access
CEChris Estes
Chris Estes
QAQuentin M. Anstee
Quentin M. Anstee
MAMaria Teresa Arias-Loste
Maria Teresa Arias-Loste
HBHeike Bantel
Heike Bantel
SBSTEFANO Bellentani
STEFANO Bellentani
HRHomie Razavi
Homie Razavi
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data. A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections. If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0-30%), between 2016-2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15-56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population. NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.

19 March 2013 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
QAQuentin M. Anstee
Quentin M. Anstee
GTGiovanni Targher
Giovanni Targher
CDChristopher P. Day
Christopher P. Day

1 May 2019 in Gastroenterology
Verified
Journal Article
Closed access
PEPeter J. Eddowes
Peter J. Eddowes
MSMagali Sasso
Magali Sasso
MAMichael Allison
Michael Allison
ETEmmanouil Tsochatzis
Emmanouil Tsochatzis
QAQuentin M. Anstee
Quentin M. Anstee
PNPhilip Noel Newsome
Philip Noel Newsome

26 April 2019 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
QAQuentin M. Anstee
Quentin M. Anstee
HRHelen L. Reeves
Helen L. Reeves
EKElena Kotsiliti
Elena Kotsiliti
OGOlivier Govaere
Olivier Govaere
MHMathias Heikenwälder
Mathias Heikenwälder